Get to know Biosion in real time
Biosion and ZhenGe Biotech Sign Global Strategic Partnership Agreement Accelerating Biosion’s Innovative Antibody Pipeline for IND Filing
NEWARK, Delaware, USA and NANJING, China, April 9,2020– Biosion Inc. and Shanghai ZhenGe Biotechnology Co. Ltd. jointly announced today that the two parties have signed a global strategic partnership agreement, to launch multiple projects with Biosion’s innovative antibody pipeline and ZhenGe’s CDMO (Contract Development and Manufacturing Organization) antibody technology platforms.
"We are very pleased to establish a strategic partnership with ZhenGeBiotech." Said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion Inc., “ZhenGe’s advanced one-stop CDMO services will facilitate CMC development of our innovative biologic pipeline and accelerate our timeline for IND filings and clinical development.”
"We look forward to working with like-minded partners," said Mr. Jianxin Chen, Founder, Chairman and CEO of ZhenGe Biotech. “Biosion’s innovative pipeline and ZhenGe’s industry leading CMC platform complement each other perfectly. I believe our cooperation will greatly promote the development of the next generation therapeutical biologics for patients in need."
According to this agreement, the two parties will leverage the competitive advantages of Biosion's innovative antibody discovery pipeline and ZhenGe’s advanced CDMO technology platforms. This partnership is expected to accelerate Biosion's innovative antibody therapeutic pipelines and at the same time take advantage of ZhenGe’s development capability and manufacturing capacity. ZhenGe will provide Biosion with strong support in process development and production efficiency to accelerate Biosion's new biologic clinical trial applications (IND) in China and globally. Details of the partnership terms were not disclosed.
About Biosion, Inc.
Biosion, Inc. is a global biotechnology company, focusing on the discovery and development of innovative therapeutics for oncology and immunological diseases. Leveraging its proprietary H³ (High-throughput, High-content, High-efficiency) antibody platform and SynAb™ technology, the company is committed to discovering and developing innovative biologics for patients with unmet medical needs. Biosion has established a proprietary therapeutic pipeline through its internal discovery efforts and collaborations with other biotech and pharmaceutical companies. For more information, please visit www.biosion.com.
About ZhenGe Biotech
Shanghai ZhenGe Biotechnology Co., Ltd., is a nationwide recognized high-tech enterprise registered in the Shanghai Free Trade Zone. ZhenGe specializes in biologics CDMO services. It has an advanced Trinity platform which integrates cell line development, process development and cell culture medium development in synergy. ZhenGe’s capabilities include customized cell culture medium development and production, cell line construction and genetic engineering, and a one-stop service system for biopharmaceutical CMC (Chemistry, Manufacturing, and Control). ZhenGe has recently closed its Series A financing, raising over $51M. Please visit www.zgbiotech.com for more information.